2017
Stereotactic Body Radiation Therapy for Oligometastatic Disease: A Multi-Institutional Retrospective Survival Analysis
Bui D, Magnuson W, Lester-Coll N, Qian J, Ross R, Soulos P, Shafman T, Dosoretz A, Evans S, Yu J, Gross C, Decker R. Stereotactic Body Radiation Therapy for Oligometastatic Disease: A Multi-Institutional Retrospective Survival Analysis. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e443. DOI: 10.1016/j.ijrobp.2017.06.1664.Peer-Reviewed Original ResearchStereotactic body radiation therapyRetrospective survival analysisBody radiation therapyOligometastatic disease
2016
A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
Stahl J, Ross R, Harder E, Mancini B, Soulos P, Dosoretz A, Finkelstein S, Shafman T, Husain Z, Evans S, Yu J, Gross C, Decker R. A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s174-s175. DOI: 10.1016/j.ijrobp.2016.06.438.Peer-Reviewed Original Research